In a report issued on November 24, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Altimmune (ALT – Research Report), with a price target of $28.00. The company’s shares closed last Friday at $10.60.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 31.2% and a 52.8% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Spectrum Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Altimmune with a $54.00 average price target.
Altimmune’s market cap is currently $333.7M and has a P/E ratio of -5.10. The company has a Price to Book ratio of 1.79.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.